7th Cancer Cachexia Conference
|
8:00 am |
Welcome and Introductory Remarks |
|
|
Session A: State-of-the-Knowledge: Clinical Fundamentals of Cancer Cachexia Co-Chairs: TBN |
|
8:10 am |
Objective metrics for cancer cachexia assessments |
8:40 am |
Endpoints in cachexic clinical trials - taking stock, moving forward Barry Laird, MBChB MRCGP MD - University of Edinburgh, Scotland, UK |
9:10 am |
Update on consensus definition of cancer cachexia |
9:40 am |
Cardiac wasting in advanced cancer & its therapeutic implications |
10:10 am |
Break |
Session B: Recent Clinical Trials and Trial Results Co-Chairs: TBN |
|
10:30 am |
Ponsegromab as a potential therapy for cancer cachexia |
11:00 am |
Central relays in cancer cachexia |
11:30 am |
Talk selected from abstract submissions |
12:00 pm |
Developing a Cachexia Lexicon |
12:15 pm |
Short talk selected from abstract submissions |
12:30 pm |
Lunch Break |
|
|
1:30 pm |
Patient-Provider-Caregiver Panel Chair: Martin Kochanczyk, PhD – Cancer Cachexia Society, USA |
|
|
Chair: TBN |
|
3:00 pm |
History of cancer cachexia research in Glasgow |
3:25 pm |
Cachexia research- the Edinburgh perspective Stephen Wigmore, Regius Chair of Clinical Surgery – University of Edinburgh, Scotland, UK |
3:45 pm |
Break |
|
|
Co-Chairs: Andrea Bonetto, PhD – University of Colorado, USA and Maria Rohm, PhD - Helmholtz Center Münich, GERMANY |
|
4:00 pm | NextGen Talk 1 from submissions |
4:15 pm | NextGen Talk 2 from submissions |
4:30 pm | NextGen Talk 3 from submissions |
4:45 pm | NextGen Talk 4 from submissions |
5:00 pm | NextGen Talk 5 from submissions |
5:15 pm | NextGen Talk 6 from submissions |
5:30 pm | *Social Events
• Whisky tasting |
7:00 am |
||
|
||
Chair: Bette Caan, DrPH - Kaiser Permanente, USA |
||
8:30 am |
The role of IL-6 in the C26 cancer cachexia model |
|
9:00 am |
CANCAN talk 2 |
|
9:30 am |
The Role of Positron Emission Tomography in Understanding Cancer Cachexia David Lewis, PhD - Cancer Research Beatson Institute, Scotland, UK |
|
9:45 am |
Working Towards a Precision Medicine Framework in Cancer Cachexia: Learning from Patients |
|
10:30 am |
Break |
|
|
||
Co-Chairs: TBN |
||
11:00 am |
Pancreatic Cancer Cachexia Min Li, PhD – The University of Oklahoma Health Sciences Center |
|
11:30 am |
Modulating Key Metabolic Pathways - Impact on Cachexia and Malnutrition Bei Zhang, PhD - Pfizer, USA |
|
12:00 pm |
Racial/ethnic heterogeneity in cancer cachexia Jose Trevino, MD - Virginia Commonwealth University, USA |
|
12:30 pm |
Short talk selected from abstracts |
|
12:45 pm |
Lunch break |
|
1:30 pm |
Poster Viewing |
|
|
||
Co-Chairs: TBN |
||
4:00 pm |
Muscle-tumor crosstalk during cancer cachexia Bert Blaauw, PhD - Veneto Institute of Molecular Medicine, ITALY |
|
4:30 pm |
Host Murf1 deletion preserves muscle and slows pancreatic cancer progression |
|
5:00 pm |
Tumor-host cross talk: delineating the reciprocal contribution of muscle wasting to tumor progression Jason Doles, PhD - Indiana University, USA |
|
5:15 pm |
Short talk selected from abstracts |
|
5:30 pm |
Short talk selected from abstracts |
|
7:00 pm |
*Dinner |
|
9:00 pm |
*Cèilidh – a traditional Scottish party |
7:00 am |
||||
|
||||
Co-Chairs: TBN |
||||
8:30 am |
Gut microbiome alterations and metabolic disorders in acute myeloid leukemia |
|||
9:00 am |
Tumor - host interactions revealed in drosophila models of cachexia |
|||
9:30 am |
Short talk selected from abstract submissions |
|||
9:45 am |
Short talk selected from abstract submissions |
|||
10:00 am |
Break |
|||
|
||||
10:15 am |
Introduction of Kenneth Fearon Lecture Speaker |
|||
10:20 am |
How Different Environments Can Influence Our Understanding of Muscle Wasting in Cancer Cachexia |
|||
|
||||
Co-Chairs: TBN |
||||
11:30 am |
Cutting Edge Talk 1 from abstracts |
|||
11:35 am |
Cutting Edge Talk 2 from abstracts |
|||
11:40 am |
Cutting Edge Talk 3 from abstracts |
|||
11:45 am |
Cutting Edge Talk 4 from abstracts |
|||
11:50 am |
Cutting Edge Talk 5 from abstracts |
|||
11:55 pm |
Cutting Edge Talk 6 from abstracts |
|||
12:00 pm |
Lunch Break |
|||
|
||||
Co-Chairs: TBN |
||||
1:30 pm |
Relationships Between Cancer Cachexia, Elevated Drug Clearance, and Immune Checkpoint Inhibitor Response Chris Coss, PhD - The Ohio State University, USA |
|||
2:00 pm |
HMGB1 in cancer cachexia |
|||
2:30 pm |
IL-6 and adaptive metabolism in cancer cachexia |
|||
2:45 pm |
Short talk selected from abstract submissions |
|||
3:00 pm |
Break |
|||
|
||||
Co-Chairs: TBN |
||||
3:30 pm |
A novel target for tumor growth and muscle wasting |
|||
4:00 pm |
Long noncoding RNAs in the regeneration of aging muscle |
|||
4:30 pm |
Age-related effects creating a permissive environment for sarcopenia David Glass, MD, PhD – Regeneron Pharmaceuticals Inc., USA |
|||
5:00 pm |
Heterogeneity of cachexia development in NSCLC Rodney Infante, MD PhD - University of Texas Southwestern Medical Center, USA |
|||
5:30 pm |
Short talk selected from abstract submissions |
|||
5:45 pm |
Presentation of awards |
|||
6:00 pm |
Closing Remarks |
*Certain social events, including the whiskey tasting, dinner and Cèilidh require additional fees.